Latest Commercialisation News

Black Canyon Limited’s June quarter report highlights robust drilling results and beneficiation success at Wandanya, supported by a $265K WA government grant and a solid $7.8 million cash position.

Reward Minerals (ASX:RWD) reported strong gold and copper assay results from its Mountain Pond Project in Newfoundland, with preparations underway for maiden drilling in the September quarter. The company also advanced its potash processing technology and ongoing discussions for the Beyondie Potash Plant in Western Australia.

1414 Degrees has secured a Heads of Agreement to develop a gigawatt-scale AI data centre precinct powered by renewable energy at its Aurora site in South Australia.

Dreadnought Resources is progressing its Star of Mangaroon open pit towards production while nearly doubling high-grade gold resources at Metzke’s Find. The company also extends critical metals potential with strong niobium and rare earth intercepts at Mangaroon.

Canadian Phosphate (ASX: CP8) has kicked off a 3,000-metre drilling campaign at its Wapiti Phosphate Project in British Columbia, aiming for a Mineral Resource Estimate by late 2026 that will support both traditional fertilizer and advanced battery material markets.

Proteomics International Laboratories has streamlined operations, secured a key US patent for its endometriosis test, and inked a three-year exclusive distribution deal with Healius for its Promarker diagnostics in Australia.

Yojee has transitioned its MOSAIC freight forwarding platform into commercial operations, securing multiple contracts including two long-term Everest Founding Partners and outlining a strategic AI-driven roadmap.

FBR Limited has partnered with Industrial Robotics LLC to distribute and support its Mantis™ welding robots across the United States and Canada, targeting key southern states and expanding its footprint without increasing headcount.

Critical Resources (ASX:CRR) spotlighted its multi-commodity pipeline and breakthrough battery cooling technology at the July 2026 TechKnow Invest Roadshow, highlighting exploration progress and exclusive global licensing deals.

BlinkLab has bolstered its war chest with a A$17.5 million placement, secured a foundational US patent valid through 2041, and made significant progress in its FDA autism diagnostic trial and European ADHD study.

BLS Pharmaceuticals capped FY26 with record revenue and EBITDA, boosted by international expansion and major contracts, setting the stage for further growth in FY27.

Nyrada has dosed the first patient in its Phase IIa trial of Xolatryp targeting heart attack recovery, while strengthening its cash reserves and receiving a US patent allowance for its lead drug.